Skip to main content
. 2020 Sep 29;9:e58108. doi: 10.7554/eLife.58108

Figure 1. COX6B2 mRNA expression correlates with poor outcome in LUAD.

(A–C) Kaplan-Meier curves for OS and FP in NSCLC (A) LUAD (B) and LUSC patients (C). (D) COX6B2 mRNA expression (RNA-seq RSEM, log2(norm count +1)) from TCGA Lung Cancer dataset. Bars represent median (normal: n = 110; tumor: n = 1017). P values calculated by Mann-Whitney test. (E–F) Whole tissue homogenates of LUAD tumors (E) and LUAD cell line lysates (F) were immunoblotted with indicated antibodies. Molecular weight (MW) markers are indicated. (G) IHC staining of non-malignant testis (a positive control), non-malignant lung (adjacent normal) and LUAD tissues. Scores ranged from 0 to 3. Scale bar, 50 μm. Bars represent mean ± SEM. p-Values calculated by Mann-Whitney test. (H) Representative confocal images of endogenous COX6B2 in HCC515 cells. Tom20 is used as a mitochondrial marker. Images were shown as Z-stack maximum projection from 0.3-μm-thick image. Scale bar, 10 μm.

Figure 1.

Figure 1—figure supplement 1. COX6B2 expression in LUAD.

Figure 1—figure supplement 1.

(A) Z-score of caspase3/7 activity screening in indicated cell lines based on data generated in Maxfield et al., 2015. (B) Top: Whole cell lysates from HCC515 depleted or COX6B2-V5 or COX6B1-V5 overexpressing cells were immunoblotted with indicated antibodies. MW markers are indicated. Bottom: Graphs COX6B1 and COX6B2 protein expression from immunoblots above. Bars represent mean ± SEM (n = 3). p-Values calculated by Student’s t-test. (C) Clinical data associated with tumors used in Figure 1E. (D) Pearson’s correlation analysis of COX6B1, COX6B2 and COXIV protein expression in LUAD tumors as measured by immunoblots in Figure 1E. Values are relative to loading control (β-Actin).